Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SYK | P43405 | 5/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MGMT | P16455 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6187792 | 0.90 | ALDH1A1 (0.54) | KMT2AALDH1A1HTTAPOBEC3AAPOBEC3G | |
| SCHEMBL30354912 | 0.87 | ALDH1A1 (0.59) | KMT2AALDH1A1HTTAPOBEC3AAPOBEC3G | |
| SCHEMBL6017266 | 0.87 | ALDH1A1 (0.59) | KMT2AALDH1A1HTTAPOBEC3AAPOBEC3G | |
| SCHEMBL29151328 | 0.85 | ALDH1A1 (0.47) | KMT2AALDH1A1HTTAPOBEC3AAPOBEC3G | |
| SCHEMBL29151259 | 0.85 | LMNA (0.43) | KMT2AALDH1A1HTTAPOBEC3AAPOBEC3G | |
| SCHEMBL30354787 | 0.85 | LMNA (0.43) | KMT2AALDH1A1HTTAPOBEC3AAPOBEC3G | |
| SCHEMBL30218362 | 0.84 | MAPT (0.58) | KMT2AALDH1A1HTTAPOBEC3AAPOBEC3G | |
| SCHEMBL29780767 | 0.84 | MAPT (0.58) | KMT2AALDH1A1HTTAPOBEC3AAPOBEC3G | |
| SCHEMBL6068967 | 0.84 | S1PR4 (0.50) | KMT2AALDH1A1HTTAPOBEC3AAPOBEC3G | |
| SCHEMBL6068707 | 0.84 | S1PR4 (0.44) | KMT2AALDH1A1MEN1MAPTSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897214-B2 | Quinazoline derivatives | ZENECA LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| EP-0880507-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| US-20030018029-A1 | Quinazoline derivatives | ZENECA LIMITED | 2003-01-23 | — | — | US | disclosed |
| US-6399602-B1 | ANTICANCER AGENTS | ZENECA LIMITED (GB) | 2002-06-04 | — | — | US | disclosed |
| US-5955464-A | USE OF THE RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES OF THE COMPOUNDS IN THE TREATMENT OF PROLIFERATIVE DISEASE SUCH AS CANCER | ZENECA LIMITED (GB) | 1999-09-21 | — | — | US | disclosed |
| EP-0794953-B1 | QUINAZOLINE DERIVATIVES | ZENECA LTD (GB) | 1999-05-06 | — | — | EP | disclosed |
| US-5866572-A | RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES, TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER. | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| EP-0880507-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0794953-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-17 | — | — | EP | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996016960-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018029-A1 | Quinazoline derivatives | ABL1, FGFR1, ERBB2 | KMT2A 953/4885ALDH1A1 1329/4885HTT 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.